NASDAQ:MDWDMediwound Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mediwound Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.11 -0.01 (-0.24 %) (As of 08/6/2020 03:03 PM ET) Add Compare Share Today's Range$3.93Now: $4.11▼$4.1150-Day Range$2.17MA: $3.43▼$4.1452-Week Range$1.44Now: $4.11▼$4.44Volume1,572 shsAverage Volume127,765 shsMarket Capitalization$111.83 millionP/E Ratio17.13Dividend YieldN/ABeta1.63 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMediwound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Mediwound has a potential upside of 55.5% from its current price of $4.02.Amount of Analyst CoverageMediwound has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesMediwound has received 366 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMediwound has received 329 “underperform” votes. (Add your “underperform” vote.)Community SentimentMediwound has received 52.66% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote “Outperform” if you believe MDWD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMediwound does not currently pay a dividend.Dividend GrowthMediwound does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mediwound insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 22.93% of the stock of Mediwound is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Mediwound are expected to grow in the coming year, from ($0.41) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mediwound is 16.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 17.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Mediwound is 16.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.95.Price to Book Value per Share RatioMediwound has a P/B Ratio of 7.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDWD Previous Symbol CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972-8932-4010Debt Debt-to-Equity Ratio0.15 Current Ratio3.08 Quick Ratio2.89Price-To-Earnings Trailing P/E Ratio17.13 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.79 million Price / Sales3.52 Cash Flow$0.13 per share Price / Cash Flow31.81 Book Value$0.56 per share Price / Book7.34Profitability EPS (Most Recent Fiscal Year)$0.08 Net Income$4.95 million Net Margins18.46% Return on Equity-75.91% Return on Assets-28.40%Miscellaneous Employees73 Outstanding Shares27,210,000Market Cap$111.83 million Next Earnings Date8/6/2020 (Confirmed) OptionableNot Optionable $4.11 -0.01 (-0.24 %) (As of 08/6/2020 03:03 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MDWD News and Ratings via Email Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Mediwound (NASDAQ:MDWD) Frequently Asked Questions How has Mediwound's stock been impacted by COVID-19 (Coronavirus)? Mediwound's stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MDWD stock has increased by 74.0% and is now trading at $4.02. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Mediwound? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mediwound. When is Mediwound's next earnings date? Mediwound is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Mediwound. How were Mediwound's earnings last quarter? Mediwound Ltd (NASDAQ:MDWD) released its earnings results on Wednesday, May, 20th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.05. The biopharmaceutical company earned $4.44 million during the quarter, compared to the consensus estimate of $4.25 million. Mediwound had a negative return on equity of 75.91% and a net margin of 18.46%. View Mediwound's earnings history. What price target have analysts set for MDWD? 2 brokerages have issued 1 year price targets for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they expect Mediwound's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 55.5% from the stock's current price. View analysts' price targets for Mediwound. Has Mediwound been receiving favorable news coverage? News stories about MDWD stock have trended somewhat positive on Thursday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mediwound earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Mediwound. Are investors shorting Mediwound? Mediwound saw a increase in short interest in July. As of July 31st, there was short interest totaling 48,100 shares, an increase of 14.5% from the July 15th total of 42,000 shares. Based on an average daily volume of 168,900 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the company's shares are sold short. View Mediwound's Current Options Chain. Who are some of Mediwound's key competitors? Some companies that are related to Mediwound include Canopy Rivers (RIV), Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Beleave (BE), Beleave (BE) and Entia Biosciences (ERGO). View all competitors. What other stocks do shareholders of Mediwound own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Co (WFC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Chubb (CB). Who are Mediwound's key executives? Mediwound's management team includes the following people: Mr. Gal Cohen, Pres & CEO (Age 46)Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)Dr. Ety Klinger, Chief R&D Officer (Age 57) What is Mediwound's stock symbol? Mediwound trades on the NASDAQ under the ticker symbol "MDWD." Who are Mediwound's major shareholders? Mediwound's stock is owned by a variety of institutional and retail investors. Top institutional investors include Thomasville National Bank (0.08%) and Harel Insurance Investments & Financial Services Ltd. (0.05%). Which institutional investors are selling Mediwound stock? MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Which institutional investors are buying Mediwound stock? MDWD stock was purchased by a variety of institutional investors in the last quarter, including Thomasville National Bank. How do I buy shares of Mediwound? Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mediwound's stock price today? One share of MDWD stock can currently be purchased for approximately $4.02. How big of a company is Mediwound? Mediwound has a market capitalization of $109.38 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis. Mediwound employs 73 workers across the globe. What is Mediwound's official website? The official website for Mediwound is www.mediwound.com. How can I contact Mediwound? Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
